Guilin Sanjin: BC006 monoclonal antibody injection new indication approved for clinical trials
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Guilin Sanjin announced that its holding subsidiary, Baochuan Biopharmaceutical Technology (Shanghai) Co., Ltd. (referred to as "Baochuan Biopharma"), has received the clinical trial approval for BC006 monoclonal antibody injection issued by the National Medical Products Administration, allowing the commencement of clinical trials for the indication of idiopathic pulmonary fibrosis
According to the Zhitong Finance APP, Guilin Sanjin (002275.SZ) announced that its controlling subsidiary, Baochuan Biopharmaceutical Technology (Shanghai) Co., Ltd. (referred to as "Baochuan Biopharmaceutical"), has received the clinical trial approval for BC006 monoclonal antibody injection issued by the National Medical Products Administration, allowing the clinical trial for the indication of idiopathic pulmonary fibrosis to proceed